simufilam
Phase 2Terminated 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Alzheimer's Disease
Conditions
Alzheimer's Disease
Trial Timeline
May 12, 2022 → Dec 31, 2024
NCT ID
NCT05352763About simufilam
simufilam is a phase 2 stage product being developed by Cassava Sciences for Alzheimer's Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT05352763. Target conditions include Alzheimer's Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06390410 | Phase 1 | Completed |
| NCT06195319 | Phase 1 | Completed |
| NCT05575076 | Phase 3 | Terminated |
| NCT05352763 | Phase 2 | Terminated |
| NCT04932655 | Phase 1 | Completed |
Competing Products
20 competing products in Alzheimer's Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY450139 + Placebo | Eli Lilly | Phase 3 | 77 |
| Solanezumab + Placebo | Eli Lilly | Phase 3 | 77 |
| LY450139 dihydrate + placebo | Eli Lilly | Phase 2 | 52 |
| GSK4527226 | Alector | Phase 2 | 44 |
| GSK4527226 | Alector | Phase 2 | 44 |
| AL002 | Alector | Phase 2 | 44 |
| Solanezumab + Placebo | Eli Lilly | Phase 3 | 77 |
| Remternetug + Placebo | Eli Lilly | Phase 3 | 77 |
| solanezumab | Eli Lilly | Phase 2 | 52 |
| LY2886721 + Placebo | Eli Lilly | Phase 1 | 33 |
| Gantenerumab + Gantenerumab + Gantenerumab + Placebo | Chugai Pharmaceutical | Phase 1 | 33 |
| Alfoatirin® Tab. + Aripezil® Tab. + Aripezil® Tab. | Yuhan | Approved | 85 |
| FK962 | Astellas Pharma | Phase 2 | 52 |
| ASP0777 + Placebo | Astellas Pharma | Phase 1 | 33 |
| Elenbecestat + Placebo | Eisai | Phase 3 | 77 |
| Donepezil | Eisai | Approved | 85 |
| Aricept (donepezil SR 23 mg) + Aricept (donepezil IR 10 mg) | Eisai | Phase 3 | 77 |
| Donepezil hydrochloride | Eisai | Phase 3 | 77 |
| Donepezil Hydrochloride | Eisai | Pre-clinical | 23 |
| Lecanemab IV + Placebo + Lecanemab SC | Eisai | Phase 3 | 77 |